CLINICAL_TRIALS
trial_result
· 2019-10-28
Clinical Trial Update: Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma [Phase 2]
Summary
Phase 2 study of durvalumab (MEDI4736) in glioblastoma has completed; results posted in 2019.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Ludwig Institute for Cancer Research | Conditions: Glioblastoma | Phase 2 | Status: COMPLETED | Results posted: 2019-10-28